Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Adding Talent to the Reset Team
Posted on April 7th, 2017 by Ross Bersot, CFA in The Hive
Last year was a significant growth year for Reset Therapeutics, in terms of our work and with our team doubling in size. Reset’s success has been due to a strict focus on our proprietary knowledge of how to modify circadian rhythms in cells, tissues and animals using novel small molecules. We have generally outsourced all off-the-shelf in vitro and in vivo assays, as well as synthetic chemistry. But as we progressed through pre-clinical studies with our lead program in 2016 and completed a partnership with Alkermes for our orexin receptor modulator program, we decided to internalize the medicinal chemistry effort and to build enhanced capability within our in vitro and in vivo biology teams.
We had dedicated support from the Board for the hiring and on-boarding process, an essential element of success for a growing company.
One of the newest members of the team is our recently-appointed COO. We were fortunate to have been introduced to Dan Oppenheimer, Ph.D. through Bay City Capital, one of our major investors, and Hoyoung Huh, M.D., Ph.D., a Board member who had worked with Dan at McKinsey. Dan had a 14-year career at BioMarin and his focus on licensing and developing drugs for orphan applications has great relevance to Reset’s cryptochrome and orexin modulators, which have applications in Cushing’s disease and narcolepsy, respectively. Dan brings business and corporate development experience along with regulatory and product development skills that complement those resident in the existing management team.
With this infusion of new leadership and new team members, we are excited to see how our work continues to progress this year.
For more information follow The Hive.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Ross Bersot, CFA
President and CEO, Reset Therapeutics
- Assessing Our Progress and Looking Ahead
- Reaxys: Increasing Efficiency in the Lab
- The Arctic Pharma Family Is Growing
- How Our Work Affects Young People – and Vice Versa
- Start-Up Spotlight: CuroNZ Ltd